Trade Marks Journal No: 1862 , 13/08/2018 CORRIGENDA

Total Page：16

File Type：pdf, Size：1020Kb

Trade Marks Journal No: 1862 , 13/08/2018 CORRIGENDA APPL CORRIGENDA DESCRIPTION NO 1467308 1467308 - (1387-0) 2109500 2109500 - (1853-0) TYPOGRAPHICAL ERROR IN THE SPECIFICATION OF GOODS IS CORRECTED TO READ AS "Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicide; herbicides." IN CLASS 05.

108

Copy Link

Recommended publications

6 X 10.5 Long Title.P65
Cambridge University Press 978-0-521-17838-9 - Inside IG Farben: Hoechst During the Third Reich Stephan H. Lindner Index More information Index Aachen Technical University, 273 Bayer AG, See IG Farben plant Elberfeld; Abs, Hermann Josef, 348 IG Farben plant Leverkusen Adenauer, Konrad, 349, 350, Behrens, Peter, 12 351, 358 Behring Werke See IG Farben plant Agfa (Aktiengesellschaft fur€ Marburg Anilinfabrikation) See IG Farben Beil, Albert, 252 plant Berlin Beitz, Berthold, 5 Allga¨u, 338 Belgium, 176, 224, 228 Allianz, 126 Benda, Louis, 155, 156, 157, 159, 169 Alsace, 139, 159 Berger, chief engineer, 162 Ambros, Otto, 1, 136, 261, 267, 285, 346, Berl, Ernst, 136, 205, 206, 210, 274 354, 359 Berlin, 39, 49, 139, 175, 224, 228, 260 Ammelburg, Alfred, 29, 41, 101, 103 Berlin University, 174 Anorgana GmbH, 359 Bertrams, Reinhold, 354 Aschersleben, 77 Best, Charles, 177 Auer, Aloys, 313, 333 Bieling, Richard, 315, 326, 327, 328, 329 Augsburg, 11, 13, 76, 77, 80 Billiter, Jean, 77, 294 Auschwitz (concentration camp), 211, 254, Binnewies, Wilhelm, 140, 141, 142, 143 309, 319, 326, 328, 333, 336, 346, 356, Black Forest, 338 358, 362 Blumrich, Karl Ferdinand, 135 Austria, 200 Bockmuhl,€ Max, 191, 301, 307, 310, 311, 316, 331, 333, 336, 342, 344 Baasch, Friedrich, 361 Boedecker, Mr., 206 Bad Orb, 238 Boker,€ Reinhard, 120 Badoglio, Pietro, 223 Bolton, Mr., 276, 312 Baeyer, Adolf von, 310 Borgermoor,€ East Frisia, 142 Baldus, Adolf, 162, 163, 248 Bormann, Mr., 97, 98 Barell, Emil, 177 Bornemann, Karl, 346 Barmen, 205 Bosch, Carl, 17, 22, 24, 25,
[Show full text]
PDF Viewing Archiving 300
I.C.FARBEN" INDUSTRIE AKTIEN" GESELLSCHAFT FRANKFURT (MAIN) 1 9 3 8 I. G. Farbenindustrie Aktiengesellschaft Frankfurt am Main Bericht des Vorstands und des Aufsichtsrats und Jahresabschluß für das Geschäftsjahr 1938. VORSTAN Geheimer Kommerzienrat Dr. HERMANN SCHMITZ, Ludwigshafen a. Rh./Heidelberg, Vorsitzer, Dr. FRITZ GAJEWSKI, Leipzig, Professor Dr. HEINRICH HäRLEIN, Wuppertal-Elberfeld, Dr. AUGUST v. KNIERIEM, Mannheim, Zentralausschuß Dr. CARL KRAUCH, Heidelberg-Schlierbach, Dr. FRITZ TER MEER, Kronberg (Taunus), Dr. CHRISTIAN SCHNEIDER, Leuna, Dr. GEORG von SCHNITZLER, Frankfurt (Main), Dr. OTTO AMBROS, Ludwigshafen a. Rh., Dr. MAX BRÜGGEMANN, Leverkusen-Wiesdorf, Dr. ERNST BÜRGIN, Bitterfeld, Dr. HEINRICH BÜTEFISCH, Leuna, Ministerialrat a. D. Dr. BERNHARD BUHL, Frankfurt (Main), PAUL HAEFLIGER, Frankfurt (Main), Dr. MAX JLGNER, Berlin-Steglitz, Dr. CONSTANTIN JACOBI, Frankfurt (Main), Dipl. Ing. FRIEDRICH JÄHNE, Frankfurt (Main), Dr. HANS KÜHNE, Leverkusen-Wiesdorf, Professor Dr. CARL LUDWIG LAUTENSCHLÄGER, Frankfurt (Main), Generalkonsul WILHELM RUDOLF MANN, Leverkusen-Wiesdorf. Dr. HEINRICH OSTER, Berlin-Charlottenburg, Kommerzialrat WILHELM OTTO, Berlin-Zehlendorf-West, Dr. OTTO SCHARF, Halle (Saale), Kommerzienrat HERMANN WAIBEL, Wiesbaden, Dr. HANS WALTHER, Frankfurt (Main), EDUARD WEBER-ANDREAE, Frankfurt (Main), Dr. CARL WURSTER, Ludwigshafen a. Rh. Im Geschäftsjahr oder nachher ausgeschieden: Kommerzienrat Dr. LUDWIG HERMANN, Frankfurt (Main) t 31. 5. 1938. AUFSICHTSRAT. Geheimer Kommerzienrat Professor Dr. CARL BOSCH, Heidelberg, Vorsitzer, Dr. WALTHER vom RATH, Kronberg (Taunus), stellvertretender Vorsitzer, Dr. WILHELM FERDINAND KALLE, Tutzing (Oberbayern), stellvertretender Vorsitzer, Dr. AXEL AUBERT, Oslo, Dr. RICHARD BAYER, Haus Falkenberg, Trills über Wuppertal-Vohwinkel, W ALDEMAR von BÖTTINGER, Landwirt, Schloß Arensdorf i. d. Neumark, Dr. WALTER von BRÜNING, Polizeipräsident a. D., Semper a. Rügen, Kommerzienrat LOTHAR BRUNCK, Kirchheimbolanden (Pfalz), Dr. CARL LUDWIG DUISBERG, Berlin-Zehlendorf-MiUe, Kommerzienrat Dr.
[Show full text]
Overview of Ftc Antitrust Actions in Pharmaceutical Services and Products
OVERVIEW OF FTC ANTITRUST ACTIONS IN PHARMACEUTICAL SERVICES AND PRODUCTS Health Care Division Bureau of Competition Federal Trade Commission Washington D.C. 20580 Markus H. Meier Assistant Director Bradley S. Albert Deputy Assistant Director Saralisa C. Brau Deputy Assistant Director September 2009 TABLE OF CONTENTS Page I. INTRODUCTION. ........................................................... 1 II. CONDUCT INVOLVING PHARMACEUTICAL SERVICES AND PRODUCTS. 3 A. Monopolization. ...................................................... 3 B. Agreements Not to Compete. ............................................ 8 C. Agreements on Price or Price-Related Terms. 14 D. Agreements to Obstruct Innovative Forms of Health Care Delivery or Financing. 20 E. Illegal Tying and Other Arrangements. .................................... 20 III. PHARMACEUTICAL MERGERS. ........................................... 20 A. Horizontal Mergers Between Direct Competitors. 20 B. Potential Competition Mergers. ......................................... 44 C. Innovation Market Mergers. ............................................ 47 D. Vertical Mergers...................................................... 49 IV. INDUSTRY GUIDANCE STATEMENTS...................................... 50 A. Advisory Opinions. ................................................... 50 B. Citizen Petition to the Food and Drug Administration. 51 V. AMICUS BRIEFS. ......................................................... 51 VI. INDICES. ............................................................
[Show full text]
Intelligent Produzieren Gute Chemie Ist Die Basis Für Vollständiges Und Qualitativ Hochwertiges Recycling
19/2013 22. Jahrgang · 10. – 23. Oktober 2013 DIE ZEITUNG FÜR DIE MÄRKTE DER CHEMIE UND LIFE SCIENCES Chemiekonjunktur Logistik Chemikalien Wachstumsdynamik Automatisierte Transportab- Nachhaltigkeitskonzepte in den BRIC-Staaten wicklung beschleunigt Prozesse und eine hohe Produktsicherheit lässt nach und bringt Sicherheit gewinnen an Bedeutung Seite 4 Seite 18 Seiten 19 – 24 Intelligent produzieren Gute Chemie ist die Basis für vollständiges und qualitativ hochwertiges Recycling oderne Nachhaltigkeits- oder Ökoeffizienzanalysen betrachten die Auswirkungen eines Produkts auf seine Umwelt über den gesamten Lebenszyklus hinweg, sozusagen von der „Wiege bis zu Bahre“. Dem M Chemiker und wissenschaftlichen Leiter des Hamburger Umweltinstituts, Prof. Michael Braungart, ist dies nicht genug: Er fordert mehr Ökoeffektivität statt Öko- effizienz bei der Entwicklung von Produkten. Mit seinem Umweltforschungs- und Beratungsinstitut EPEA berät er Unternehmen aus aller Welt bei der Umsetzung sei- nes Prinzips „Cradle-to-Cradle“ (von der Wiege zur Wiege). Dr. Andrea Gruß sprach mit Prof. Braungart darüber, warum „gute“ Chemie mehr als nachhaltig sein muss. CHEManager: Herr Braungart, auf Qualität und Schönheit setzen immer mehr Unternehmen ent- und nicht auf Nachhaltigkeit. Dann wickeln Produkte nach Prinzipien entstehen Innovationen. der „grünen“ Chemie. Führt dies Der Begriff Nachhaltigkeit ist zu einer höheren Produktqualität? auch langweilig. Es geht dabei im- mer nur darum, zu reduzieren, zu Prof. M. Braungart: Es gibt keine ‚grü- minimieren und zu sparen. Das ne‘ Chemie, es gibt nur gute oder heißt, alles wie bisher zu machen, N EWSFLOW schlechte Chemie. Chemie, die sich nur eben weniger schlecht. Doch in Lebewesen anreichert, hat ein weniger schlecht ist noch lange - Fotolia.com © aleciccotelli Unternehmen Qualitätsproblem. Chemie, die Abfäl- nicht gut.
[Show full text]
I.G. Farben's Petro-Chemical Plant and Concentration Camp at Auschwitz Robert Simon Yavner Old Dominion University
Old Dominion University ODU Digital Commons History Theses & Dissertations History Summer 1984 I.G. Farben's Petro-Chemical Plant and Concentration Camp at Auschwitz Robert Simon Yavner Old Dominion University Follow this and additional works at: https://digitalcommons.odu.edu/history_etds Part of the Economic History Commons, and the European History Commons Recommended Citation Yavner, Robert S.. "I.G. Farben's Petro-Chemical Plant and Concentration Camp at Auschwitz" (1984). Master of Arts (MA), thesis, History, Old Dominion University, DOI: 10.25777/7cqx-5d23 https://digitalcommons.odu.edu/history_etds/27 This Thesis is brought to you for free and open access by the History at ODU Digital Commons. It has been accepted for inclusion in History Theses & Dissertations by an authorized administrator of ODU Digital Commons. For more information, please contact [email protected]. 1.6. FARBEN'S PETRO-CHEMICAL PLANT AND CONCENTRATION CAMP AT AUSCHWITZ by Robert Simon Yavner B.A. May 1976, Gardner-Webb College A Thesis Submitted to the Faculty of Old Dominion University in Partial Fulfillment of the Requirements for the Degree of MASTER OF ARTS HISTORY OLD DOMINION UNIVERSITY August 1984 Approved by: )arw±n Bostick (Director) Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. Copyright by Robert Simon Yavner 1984 All Rights Reserved Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. ABSTRACT I.G. FARBEN’S PETRO-CHEMICAL PLANT AND CONCENTRATION CAMP AT AUSCHWITZ Robert Simon Yavner Old Dominion University, 1984 Director: Dr. Darwin Bostick This study examines the history of the petro chemical plant and concentration camp run by I.G.
[Show full text]
The Persistence of Elites and the Legacy of I.G. Farben, A.G
Portland State University PDXScholar Dissertations and Theses Dissertations and Theses 5-7-1997 The Persistence of Elites and the Legacy of I.G. Farben, A.G. Robert Arthur Reinert Portland State University Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds Part of the History Commons Let us know how access to this document benefits ou.y Recommended Citation Reinert, Robert Arthur, "The Persistence of Elites and the Legacy of I.G. Farben, A.G." (1997). Dissertations and Theses. Paper 5302. https://doi.org/10.15760/etd.7175 This Thesis is brought to you for free and open access. It has been accepted for inclusion in Dissertations and Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [email protected]. THESIS APPROVAL The abstract and thesis of Robert Arthur Reinert for the Master of Arts in History were presented May 7, 1997, and accepted by the thesis committee and department. COMMITTEE APPROVALS: Sean Dobson, Chair ~IReard~n Louis Elteto Representative of the Office of Graduate Studies DEPARTMENT APPROVAL: [)fl Dodds Department of History * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ACCEPTED FOR PORTLAND STATE UNIVERSITY BY THE LIBRARY by on ct</ ~~ /997 ABSTRACT An abstract of the thesis of Robert Arthur Reinert for the Master of Arts in History presented May 7, 1997. Title: The Persistence of Elites and the Legacy of LG. Farben, A.G .. On a massive scale, German business elites linked their professional ambitions to the affairs of the Nazi State. By 1937, the chemical giant, l.G. Farben, became completely "Nazified" and provided Hitler with materials which were essential to conduct war.
[Show full text]
Scheduling Order
Case 2:16-cv-12943-SSV-JCW Document 1 Filed 07/19/16 Page 1 of 36 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF LOUISIANA VERONICA A. SMITH Plaintiff, v. Civil Action No.______________ SANOFI S.A., AVENTIS PHARMA S.A., and Section: __________ SANOFI-AVENTIS U.S. LLC, separately, and doing business as WINTHROP U.S. Defendants. COMPLAINT AND JURY DEMAND Plaintiff, Veronica A. Smith, by and through her attorneys, respectfully submits the following Complaint and Jury Demand against Defendants Sanofi S.A.; Aventis Pharma S.A.; and Sanofi-Aventis U.S. LLC, separately, and doing business as Winthrop U.S. (“Defendants”), and alleges the following: NATURE OF THE ACTION 1. This action seeks to recover damages for injuries sustained by Plaintiff as the direct and proximate result of the wrongful conduct of Defendants, Sanofi S.A., Aventis Pharma S.A., and Sanofi-Aventis U.S. LLC, in connection with the designing, developing, manufacturing, distributing, labeling, advertising, marketing, promoting, and selling of TAXOTERE®, a prescription medication used in the treatment of breast cancer. Case 2:16-cv-12943-SSV-JCW Document 1 Filed 07/19/16 Page 2 of 36 JURISDICTION AND VENUE 2. This Court has subject matter jurisdiction pursuant to 28. U.S.C. § 1332 (diversity jurisdiction). The amount in controversy exceeds $75,000.00 exclusive of interest and costs. There is complete diversity of citizenship between Plaintiff and Defendants. Plaintiff is a resident and citizen of and is domiciled in the State of Louisiana, within St. John the Baptist Parish. As set forth more fully below, all Defendants are entities organized in states other than the State of Louisiana, all Defendants have their principal place of business in a state other than the State of Louisiana, and none of the Defendants is a citizen or resident of the State of Louisiana.
[Show full text]
Military Tribunal, Indictments
MILITARY TRIBUNALS CASE No.6 THE UNITED STATES OK AMERICA -against- CARL KRAUCH, HERMANN SCHMITZ, GEORG VON SCHNITZLER, FRITZ GAJEWSKI, HEINRICH HOERLEIN, AUGUST VON KNIERIEM, FRITZ.a'ER MEER, CHRISTIAN SCHNEIDER, OTTO AMBROS, MAX BRUEGGEMANN, ERNST BUERGIN, HEINRICH BUETEFISCH, PAUL HAEFLIGER, MAX ILGNER, FRIEDRICH JAEHNE,. HANS KUEHNE, CARL LAUTENSCHLAEGER, WILHELM MANN, HEINRICH OSTER, KARL WURSTER, WALTER DUERR FELD, HEINRICH GATTINEAU, ERICH VON DER HEYDE, and HANS KUGLER, officialS of I. G. F ARBENINDUSTRIE AKTIENGESELLSCHAFT Defendants OFFICE OF MILITARY GOVERNMENT FOR GERMANY (US) NURNBERG 1947 PURL: https://www.legal-tools.org/doc/1e951a/ 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 PURL: https://www.legal-tools.org/doc/1e951a/ 1 TABLE OF CONTENTS INTRODUCTORY 5 COUNT ONE-PLANNING, PREPARATION, INITIATION AND WAGING OF WARS OF AGGRESSION AND INVASIONS OF OTHER COUNTRIES 9 STATEMENT OF THE OFFENSE 9 PARTICULARS OF DEFENDANTS' PARTICIPATION 9 A. The Alliance of FARBEN with Hitlet· and the Nazi Party 9 B. F ARBEN synchronized all of its activities with the military planning of the German High Command 13 C. FARBEN participated in preparing the Four Year Plan and in directing the economic mobilization of Germany for war 15 D. F ARBEN participated in creating and equipping the Nazi military machine for aggressive war. 20 E. F ARB EN procured and stockpiled critical war materials . for the Nazi offensive / 22 F. FARBEN participated in weakening Germany's potential enemies 23 G. FARBEN carried on propaganda, intelligence, and espionage activ:ities 25 H. With the approach of war and with each new act of aggression, F ARBEN intensified its preparation for, and participation in, the planning and execution of such aggressions and the reaping of spoils therefrom 27 I.
[Show full text]
PDF Viewing Archiving 300
I.C.FARBEN INDUSTRIE AKTIEN~ GESELLSCHAFT FRANKFURT(.MAIN) 1 9 3 2 L G. Farbenindustrie Aktiengesellschaft Frankfurt (Main) Bericht· des Vorstandes und des Aufsichtsrates über das Geschäftsjahr 1932. 8. ordentliche Generalversammlung Freitag, den 28. April 1933, vormittags 11 Uhr, in unserem Verwaltungsgebäude Frankfurt (Main) Grüneburgplatz. Tages-Ordnung: 1. Vorlage des Jahresabschlusses und des Geschäftsberichtes für 1932 und Beschlußfassung über den Jahresabschluß. 2. Gewinnverteilung. 3. Entlastung des Aufsichtsrates und des Vorstandes. 4. Wahlen zum Aufsichtsrat. 5. Wahl des Bilanzprüfers fUr das Geschäftsjahr 1933. Aufsi chtsrat. Geheimer Regierungsrat Professor Dr. CARL DUISBERG, Leverkusen, Vorsitzender, Dr. CARL von WEINBERG, Frankfurt (Main)-Niederrad, stellvertretender Vorsitzender, Dr. WTLHELM FERDINAND KALLE, Frankfurt (Main), Dr. RUDOLF MANN, Leverkusen, Verwaltungsrat Geheimer Kommerzienrat Dr. LUDWIG SCHUON, München, Staatssekretär z. D. Dr. ERNST von SIMSON, Berlin-Dahlem, Geheimer Regierungsrat Dr. ARTHUR von WEINBERG, Frankfurt (Main)-Niederrad. J Dr. WALTHER vom RATH, Cronberg (Taunus), Kommerzienrat ADOLF KÄCHELEN, Stuttgart, stellvertretender Vorsitzender, Wirkt. Geheimer Oberregierungsrat Dr. WILHELM von Dr. AXEL AUBERT, Oslo. MEISTER, Regierungspräsident a. D., Genf. Geheimer Hofrat Dr. GUST AV AUFSCHLÄGER, Hamburg, OTTO von MENDELSSOHN-BARTHOLDY, Berlin, Dr. RICHARD BAYER, Leverkusen, Dr. ALFRED MERTON, Frankfurt (Main), WALDEMAR von BöTTINGER, Rittergutsbesitzer, WILHELM PELTZER, Fabrikant, Krefeld, Schloss Arensdorf i. d. Neumark, Dr. W ALTER von BRONING, Polizeipräsident a. D., JULIUS SCHARFF, Bad Liebenzell, Semper a. Rügen, Graf RUTGER JAN EUGEN SCHIMMELPENNINCK, Kommerzienrat LOTHAR BRUNCK, Kirchheimbolanden, Den Haag (Holland), Geheimer Kommerzienrat Dr. LEO GANS, Dr. OSCAR SCHLITTER, Berlin, Frankfurt (Main), Geheimer Regierungsrat Dr. ADOLF HAEUSER, Staatsminister Dr. FRIEDRICH SCHMIDT -OTT, Frankfurt (Main), Exzellenz, Berlin-Steglitz, Dr. JAKOB HASSLACHER, Duisburg-Ruhrort, LEOPOLD Freiherr von SCHRENCK-NOTZING, Berlin.
[Show full text]
TAXOTERE (DOCETAXEL) MDL No
Case 2:16-cv-17144 Document 1 Filed 12/12/16 Page 1 of 101 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF LOUISIANA IN RE: TAXOTERE (DOCETAXEL) MDL No. 2740 PRODUCTS LIABILITY LITIGATION SECTION “N” (5) HON. KURT D. ENGLELHARDT BARBARA EARNEST Plaintiff, MAG. JUDGE NORTH vs. COMPLAINT & JURY DEMAND SANOFI S.A., Civil Action No. __________ AVENTIS PHARMA S.A., and SANOFI-AVENTIS U.S. LLC, separately, and doing business as WINTHROP U.S HOSPIRA WORLDWIDE, INC.; and SUN PHARMA GLOBAL INC.; and McKESSON CORPORATION d/b/a McKESSON PACKAGING; and SANDOZ INC.; and ACCORD HEALTHCARE INC.; and APOTEX, INC.; and PFIZER, INC.; and ACTAVIS PHARMA, INC.; and NORTHSTAR RX LLC; and EAGLE PHARMACEUTICALS, INC. Defendants. COMPLAINT AND JURY DEMAND Plaintiff, Barbara Earnest, by and through her attorneys, Bachus & Schanker, LLC, respectfully submits the following Complaint and Jury Demand against Defendants Sanofi S.A.; Aventis Pharma S.A.; and Sanofi-Aventis U.S. LLC, separately,; and doing business as Winthrop Case 2:16-cv-17144 Document 1 Filed 12/12/16 Page 2 of 101 U.S and Hospira Worldwide, Inc.; and Sun Pharma Global Inc.; and McKesson Corporation d/b/a McKesson Packaging; and Sandoz Inc.; and Accord Healthcare Inc..; and Apotex, Inc.; and Pfizer, Inc.; and Actavis Pharma, Inc.; and Northstar Rx LLC; and Eagle Pharmaceuticals, Inc., and alleges the following upon personal knowledge, information and belief, and investigation of counsel. NATURE OF THE ACTION 1. This action seeks to recover damages for injuries sustained by Plaintiff as the direct and proximate result of the wrongful conduct of Defendants Sanofi S.A., Aventis Pharma S.A., and Sanofi-Aventis U.S.
[Show full text]
Robert J. Desalvo Papers Business Combinations in the Cosmetic and Pharmaceutical Industries 1944
Robert J. DeSalvo Papers Business Combinations in the Cosmetic and Pharmaceutical Industries 1944 - 1990 Collection #107 Abstract Robert J. DeSalvo’s research focused on business combinations (acquisitions, mergers, and joint ventures in the cosmetic and pharmaceutical industries. This topic was the basis for his master’s thesis in pharmacy administration at the University of Pittsburgh and continued as a life-long interest. This collection consists of two series of notebooks that Dr. DeSalvo developed to record relevant business combinations. The first series records acquisitions, proposed acquisitions, mergers, and joint ventures for the period of 1944 –1990 in an alphabetical arrangement. The information on these entries is cumulative so that the history of an organization is collected in one place. The second series of notebooks is arranged in chronological blocks. The information is arranged alphabetically by the name of the acquirer. The name of the acquired (merged), type of combination (acquisition, proposed acquisition, joint venture) and the date is also provided. The information is cross-referenced between the two series so that the researcher can approach the information by the name of the parent company or chronologically. Dr. DeSalvo used this resource for many of his publications as well as his master’s thesis. A copy of these publications and his thesis make up the remainder of the collection. Donor Gift of Barbara DeSalvo, 2000 Biography Robert James DeSalvo was born on July 20, 1933 in Toledo, OH. He died on January 23, 1993 in Cincinnati, OH. DeSalvo graduated from high school in Toledo and attended pharmacy school at the University of Toledo where he received his B.S.
[Show full text]
Complaint (PDF)
Case 2:16-cv-10763 Document 1 Filed 06/17/16 Page 1 of 36 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF LOUISIANA CAROL WEBB Plaintiff, v. Civil Action No.______________ SANOFI S.A., AVENTIS PHARMA S.A., and Section: __________ SANOFI-AVENTIS U.S. LLC, separately, and doing business as WINTHROP U.S. Defendants. COMPLAINT AND JURY DEMAND Plaintiff, Carol Webb, by and through her attorneys, respectfully submits the following Complaint and Jury Demand against Defendants Sanofi S.A.; Aventis Pharma S.A.; and Sanofi- Aventis U.S. LLC, separately, and doing business as Winthrop U.S. (“Defendants”), and alleges the following: NATURE OF THE ACTION 1. This action seeks to recover damages for injuries sustained by Plaintiff as the direct and proximate result of the wrongful conduct of Defendants, Sanofi S.A., Aventis Pharma S.A., and Sanofi-Aventis U.S. LLC, in connection with the designing, developing, manufacturing, distributing, labeling, advertising, marketing, promoting, and selling of TAXOTERE®, a prescription medication used in the treatment of breast cancer. Case 2:16-cv-10763 Document 1 Filed 06/17/16 Page 2 of 36 JURISDICTION AND VENUE 2. This Court has subject matter jurisdiction pursuant to 28. U.S.C. § 1332 (diversity jurisdiction). The amount in controversy exceeds $75,000.00 exclusive of interest and costs. There is complete diversity of citizenship between Plaintiff and Defendants. Plaintiff is a resident and citizen of and is domiciled in the State of Louisiana. As set forth more fully below, all Defendants are entities organized in states other than the State of Louisiana, all Defendants have their principal place of business in a state other than the State of Louisiana, and none of the Defendants is a citizen or resident of the State of Louisiana.
[Show full text]